@article {1051146,
	title = {Summary and Recommendations from the National Cancer Institute{\textquoteright}s Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer},
	journal = {Bladder Cancer},
	volume = {2},
	number = {2},
	year = {2016},
	month = {2016 Apr 27},
	pages = {165-202},
	abstract = {The NCI Bladder Cancer Task Force convened a Clinical Trials Planning Meeting (CTPM) Workshop focused on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer (NMIBC). Meeting attendees included a broad and multi-disciplinary group of clinical and research stakeholders and included leaders from NCI, FDA, National Clinical Trials Network (NCTN), advocacy and the pharmaceutical and biotech industry. The meeting goals and objectives were to: 1) create a collaborative environment in which the greater bladder research community can pursue future optimally designed novel clinical trials focused on the theme of molecular targeted and immune-based therapies in NMIBC; 2) frame the clinical and translational questions that are of highest priority; and 3) develop two clinical trial designs focusing on immunotherapy and molecular targeted therapy. Despite successful development and implementation of large Phase II and Phase III trials in bladder and upper urinary tract cancers, there are no active and accruing trials in the NMIBC space within the NCTN. Disappointingly, there has been only one new FDA approved drug (Valrubicin) in any bladder cancer disease state since 1998. Although genomic-based data for bladder cancer are increasingly available, translating these discoveries into practice changing treatment is still to come. Recently, major efforts in defining the genomic characteristics of NMIBC have been achieved. Aligned with these data is the growing number of targeted therapy agents approved and/or in development in other organ site cancers and the multiple similarities of bladder cancer with molecular subtypes in these other cancers. Additionally, although bladder cancer is one of the more immunogenic tumors, some tumors have the ability to attenuate or eliminate host immune responses. Two trial concepts emerged from the meeting including a window of opportunity trial (Phase 0) testing an FGFR3 inhibitor and a second multi-arm multi-stage trial testing combinations of BCG or radiotherapy and immunomodulatory agents in patients who recur after induction BCG (BCG failure).},
	issn = {2352-3727},
	doi = {10.3233/BLC-160053},
	author = {Lerner, Seth P and Bajorin, Dean F and Dinney, Colin P and Efstathiou, Jason A and Groshen, Susan and Hahn, Noah M and Hansel, Donna and Kwiatkowski, David and O{\textquoteright}Donnell, Michael and Rosenberg, Jonathan and Svatek, Robert and Abrams, Jeffrey S and Al-Ahmadie, Hikmat and Apolo, Andrea B and Bellmunt, Joaquim and Callahan, Margaret and Cha, Eugene K and Drake, Charles and Jarow, Jonathan and Kamat, Ashish and Kim, William and Knowles, Margaret and Mann, Bhupinder and Marchionni, Luigi and McConkey, David and McShane, Lisa and Ramirez, Nilsa and Sharabi, Andrew and Sharpe, Arlene H and Solit, David and Tangen, Catherine M and Amiri, Abdul Tawab and Van Allen, Eliezer and West, Pamela J and Witjes, J A and Quale, Diane Zipursky}
}
